Mario Assenmacher
Overview
Explore the profile of Mario Assenmacher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1121
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aleksandrova K, Leise J, Priesner C, Aktas M, Apel M, Assenmacher M, et al.
Front Immunol
. 2024 Oct;
15:1328368.
PMID: 39386211
Introduction: Point-of-care (POC) manufacturing of chimeric antigen receptor (CAR) modified T cell has expanded rapidly over the last decade. In addition to the use of CD19 CAR T cells for...
2.
Pfeifer R, Al Rawashdeh W, Brauner J, Martinez-Osuna M, Lock D, Herbel C, et al.
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298141
Due to the paucity of targetable antigens, triple-negative breast cancer (TNBC) remains a challenging subtype of breast cancer to treat. In this study, we developed and evaluated a chimeric antigen...
3.
Werchau N, Kotter B, Criado-Moronati E, Gosselink A, Cordes N, Lock D, et al.
Oncoimmunology
. 2022 Nov;
11(1):2140534.
PMID: 36387056
Solid tumors consist of malignant and nonmalignant cells that together create the local tumor microenvironment (TME). Additionally, the TME is characterized by the expression of numerous soluble factors such as...
4.
Cordes N, Winter N, Kolbe C, Kotter B, Mittelstaet J, Assenmacher M, et al.
Viruses
. 2022 Oct;
14(10).
PMID: 36298713
Selective gene delivery to a cell type of interest utilizing targeted lentiviral vectors (LVs) is an efficient and safe strategy for cell and gene therapy applications, including chimeric antigen receptor...
5.
Lock D, Monjezi R, Brandes C, Bates S, Lennartz S, Teppert K, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36096530
Background: There is an increasing demand for chimeric antigen receptor (CAR) T cell products from patients and care givers. Here, we established an automated manufacturing process for CAR T cells...
6.
Kotter B, Engert F, Krueger W, Roy A, Al Rawashdeh W, Cordes N, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638227
Chimeric antigen receptor (CAR) T cell therapy has emerged as an attractive strategy for cancer immunotherapy. Despite remarkable success for hematological malignancies, excessive activity and poor control of CAR T...
7.
Cordes N, Kolbe C, Lock D, Holzer T, Althoff D, Schafer D, et al.
Mol Ther Methods Clin Dev
. 2021 Mar;
21:42-53.
PMID: 33768128
Recently, a rare type of relapse was reported upon treating a B cell acute lymphoblastic leukemia (B-ALL) patient with anti-CD19 chimeric antigen receptor (CAR)-T cells caused by unintentional transduction of...
8.
Bacher P, Hohnstein T, Beerbaum E, Rocker M, Blango M, Kaufmann S, et al.
Cell
. 2019 Feb;
176(6):1340-1355.e15.
PMID: 30799037
Th17 cells provide protection at barrier tissues but may also contribute to immune pathology. The relevance and induction mechanisms of pathologic Th17 responses in humans are poorly understood. Here, we...
9.
Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser A, et al.
Cancer Immunol Immunother
. 2018 Apr;
67(7):1053-1066.
PMID: 29605883
Relapsed/refractory B-precursor acute lymphoblastic leukemia (pre-B ALL) remains a major therapeutic challenge. Chimeric antigen receptor (CAR) T cells are promising treatment options. Central memory T cells (Tcm) and stem cell-like...
10.
Lock D, Mockel-Tenbrinck N, Drechsel K, Barth C, Mauer D, Schaser T, et al.
Hum Gene Ther
. 2017 Aug;
28(10):914-925.
PMID: 28847167
The clinical success of gene-engineered T cells expressing a chimeric antigen receptor (CAR), as manifested in several clinical trials for the treatment of B cell malignancies, warrants the development of...